VLP Therapeutics was featured in Asahi Shinbun (November 10, 2016)
VLP Therapeutics was featured in Asahi Shinbun (November 10, 2016)
VLP Therapeutics was featured in Asahi Shinbun (November 10, 2016)
VLP Therapeutics was featured in Nikkei Biotech Online (October 11, 2016). https://bio.nikkeibp.co.jp/atcl/news/p1/16/10/09/01662/
Gaithersburg, Md.-- (PR NEWS WIRE) — October 5, 2016 -- VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology Fund (“the GHIT Fund”) for early-stage research to develop new vaccines for dengue fever using virus-like particles that would target all four strains of the
Gaithersburg, Md.-- (PR NEWS WIRE) — July 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, announced that it won a $2.4 million Peer Reviewed Medical Research Program Technology/Therapeutic
Gaithersburg, Md.— March 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary i-α VLP vaccine technology, today announced that Louis M. Weiner, M.D., Director of Georgetown Lombardi Comprehensive Cancer Center, has
Gaithersburg, Md.-- (PR NEWS WIRE) — February 27, 2016 -- VLP Therapeutics LLC (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next-generation antibody agents based upon a novel and proprietary i-α VLP vaccine technology, today announced that it received a Maryland Industrial Partnership (MIPS) grant award
Gaithersburg, Md.—February 8, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,249,191, Virus Like Particle Composition. The patent protects key composition of matter of VLP’s proprietary i-α virus like particles platform technology, and the pharmaceutical composition and vaccine for use
“Structural Studies of Chikungunya Virus-like Particles 2 Complexed with Human Antibodies: Neutralization and 3 Cell-to-Cell Transmission” Jason Porta, Vidya Mangala Prasad, Cheng-I Wang, Wataru Akahata, Lisa F.P. Ng, Michael G. Rossmann http://jvi.asm.org/content/early/2015/10/30/JVI.02364-15.full.pdf+html
VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, was invited to speak at the 2015 Dasan Conference in Busan, Korea on Wednesday, December 2, 2015, at 3:00 p.m. Local Time. The event, which is hosted by the Korean Federation of Science and Technology Societies (KOFST) is titled “the Development of Novel Technology for the Preparedness of Emerging and Unknown Infectious Diseases”and take place at Saintmare, Busan, Korea.
“Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.” Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE Jr, Diamond MS, Rossmann MG.